Introduction Pancreatic cancer is one of the deadliest solid organ cancers. In the absence of
specific warning symptoms pancreatic cancer is diagnosed notoriously late. Current …

The current treatment options for pancreatic ductal adenocarcinoma fall exceedingly short of
a cure, providing a sobering 5-year survival rate of only 5% for all patients, and the disease …

Introduction: Pancreatic cancer, the incidence and mortality of which are increasing around
the world, has the most dismal prognosis among the commonly encountered cancers …

Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is
projected to become a leading cause of cancer-related death in coming years. Improving …

Pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer) carries one of the poorest
overall prognoses of all human malignancies known to date. Despite the introduction of …

Simple Summary The lack of early diagnosis and the absence of suitable biomarkers
coupled with resistance to available therapeutic options render pancreatic cancer one of the …

Introduction Despite the considerable progress made in cancer treatment through the
development of target therapies, pancreatic ductal adenocarcinoma (PDAC) continues to …

Pancreatic cancer is still diagnosed at a late stage although we have novel diagnostic tools.
Pancreatic cancer chemotherapy treatment resistance is observed and therefore novel …

Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading
cause of cancer-related death in North America. Most patients present with locally advanced …

Pancreatic cancer is the fourth leading cause of cancer death in the US and is expected to
become the second leading cause of cancer-related deaths in the next decade. Despite 5 …